Hospital
Veritas Health Services, LLC
Veritas Health Services, LLC was paid $14.93M by Medicaid between Jan 2018 and Dec 2024, across 181 billing codes. Its largest line is 0450, Emergency room services — 24% of everything it billed.
33Billing provider infoVERITAS HEALTH SERVICES, LLC
CHINO, CA 91710
CHINO, CA 91710
33aNPI1962407460assigned 06/20/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.93M
24GClaims618,248
24DCodes billed181
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#152 of 410
Median peer was paid$6.90M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 101,426 | $2.17M | |
| 2019 | 102,934 | $2.15M | |
| 2020 | 69,154 | $1.70M | |
| 2021 | 77,210 | $1.95M | |
| 2022 | 85,519 | $2.21M | |
| 2023 | 100,118 | $2.61M | |
| 2024incomplete | 81,887 | $2.14M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 24% | 80,040 | 71,167 | $3.60M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 31,056 | 28,193 | $1.57M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.5% | 4,899 | 4,781 | $677K |
| Z7502 | 4.2% | 16,628 | 16,399 | $625K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.1% | 10,629 | 10,050 | $611K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.6% | 4,740 | 4,639 | $544K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.8% | 17,475 | 16,375 | $421K |
| 80053 | Comprehensive metabolic panel | 2.8% | 26,946 | 25,081 | $412K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.5% | 10,526 | 10,187 | $374K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.5% | 16,682 | 15,663 | $369K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 35,171 | 32,254 | $317K |
| 93976 | 1.8% | 1,390 | 1,352 | $262K |
169 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.7% | 3,113 | $250K |
| 71045 | Radiologic examination, chest; single view | 1.6% | 18,301 | $238K |
| 99499 | 1.6% | 3,754 | $233K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 4,166 | $226K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.5% | 1,754 | $226K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 7,770 | $201K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 2,560 | $181K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 821 | $177K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 8,643 | $158K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.0% | 2,813 | $154K |
| 99199 | Unlisted special service, procedure or report | <1% | 3,011 | $127K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,164 | $125K |
| 81025 | <1% | 19,259 | $117K | |
| 83690 | <1% | 14,020 | $116K | |
| 84484 | <1% | 10,363 | $115K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 12,064 | $102K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,398 | $99K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 864 | $97K |
| 83880 | <1% | 3,987 | $91K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 451 | $80K |
| 99070 | <1% | 16,953 | $80K | |
| 81002 | <1% | 17,919 | $66K | |
| 99285 | Emergency room visit (most serious) | <1% | 471 | $65K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,633 | $63K |
| J3490 | Unclassified drugs | <1% | 18,765 | $62K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,022 | $61K |
| 90715 | <1% | 1,800 | $57K | |
| 73610 | <1% | 2,306 | $56K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,140 | $53K |
| 87040 | <1% | 4,174 | $50K | |
| 73562 | <1% | 2,253 | $48K | |
| 83605 | <1% | 3,659 | $44K | |
| 73630 | <1% | 1,842 | $41K | |
| 99284 | Emergency room visit (serious) | <1% | 805 | $40K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,681 | $39K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,405 | $39K |
| 0370 | <1% | 344 | $39K | |
| 81001 | <1% | 8,554 | $37K | |
| 73030 | <1% | 1,597 | $36K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,501 | $36K |
| 74018 | <1% | 1,869 | $36K | |
| 73130 | <1% | 1,530 | $35K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 720 | $35K |
| 73110 | <1% | 1,445 | $34K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,586 | $33K |
| 82550 | <1% | 3,936 | $32K | |
| 72100 | <1% | 1,153 | $30K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 308 | $29K |
| 84702 | <1% | 1,905 | $27K | |
| 87070 | <1% | 2,581 | $26K | |
| 87430 | <1% | 2,268 | $25K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 374 | $23K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,617 | $23K |
| 84480 | <1% | 1,210 | $20K | |
| 85730 | <1% | 3,140 | $20K | |
| 76830 | Ultrasound, transvaginal | <1% | 384 | $20K |
| 87420 | <1% | 1,870 | $19K | |
| 93971 | <1% | 198 | $19K | |
| 99406 | <1% | 1,849 | $19K | |
| 29125 | <1% | 1,798 | $18K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 356 | $18K |
| 73080 | <1% | 709 | $17K | |
| 83735 | <1% | 2,366 | $16K | |
| 85610 | <1% | 3,537 | $16K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 986 | $16K |
| Z7610 | <1% | 1,052 | $16K | |
| 82150 | <1% | 1,747 | $15K | |
| 0710 | <1% | 655 | $15K | |
| 82962 | <1% | 3,626 | $14K | |
| 73140 | <1% | 944 | $14K | |
| 87186 | <1% | 1,498 | $14K | |
| 0250 | <1% | 2,333 | $14K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,490 | $14K |
| 80076 | <1% | 1,689 | $13K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 219 | $12K |
| 81003 | <1% | 3,957 | $11K | |
| 12001 | <1% | 593 | $11K | |
| 84436 | <1% | 1,441 | $11K | |
| 85378 | <1% | 1,255 | $11K | |
| 80061 | Lipid panel | <1% | 845 | $11K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,967 | $10K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 903 | $10K |
| 0270 | <1% | 2,637 | $9K | |
| 76376 | <1% | 1,171 | $9K | |
| 87077 | <1% | 1,541 | $8K | |
| 84439 | <1% | 787 | $8K | |
| 86901 | <1% | 1,729 | $8K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,875 | $7K |
| Q0092 | Set-up portable x-ray equipment | <1% | 907 | $7K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 3,054 | $6K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,261 | $6K |
| 86900 | <1% | 1,729 | $6K | |
| 82140 | <1% | 452 | $6K | |
| 86140 | <1% | 951 | $6K | |
| 83718 | <1% | 600 | $5K | |
| 29515 | <1% | 453 | $5K | |
| G0378 | Hospital observation service, per hour | <1% | 87 | $5K |
| 84703 | <1% | 528 | $5K | |
| 87428 | <1% | 63 | $4K | |
| 74022 | <1% | 131 | $4K | |
| 71101 | <1% | 127 | $4K | |
| 10060 | <1% | 222 | $4K | |
| 29505 | <1% | 382 | $4K | |
| 73590 | <1% | 206 | $4K | |
| 83721 | <1% | 399 | $4K | |
| 82803 | <1% | 165 | $4K | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 128 | $3K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,364 | $3K |
| 12011 | <1% | 169 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,646 | $3K |
| 73090 | <1% | 189 | $3K | |
| 84479 | <1% | 453 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,127 | $3K |
| 73502 | <1% | 101 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 424 | $3K |
| 76801 | <1% | 43 | $3K | |
| 82465 | <1% | 715 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,342 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 248 | $2K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,049 | $2K |
| 99221 | <1% | 12 | $2K | |
| 0011A | <1% | 52 | $2K | |
| 29130 | <1% | 245 | $2K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 71 | $2K |
| 86885 | <1% | 272 | $2K | |
| 0012A | <1% | 46 | $2K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 712 | $2K |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,877 | $1K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 93 | $996.80 |
| 82009 | <1% | 162 | $846.41 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,983 | $736.52 |
| 36600 | <1% | 95 | $646.67 | |
| 84100 | <1% | 197 | $619.34 | |
| 12002 | <1% | 42 | $599.36 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 43 | $564.72 |
| 85651 | <1% | 142 | $510.06 | |
| 82947 | <1% | 139 | $478.59 | |
| 82728 | <1% | 27 | $387.40 | |
| 72040 | <1% | 15 | $343.22 | |
| 87205 | <1% | 74 | $336.71 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 12 | $249.36 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,119 | $229.69 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 22 | $203.07 |
| 83615 | <1% | 28 | $196.18 | |
| 71010 | <1% | 13 | $193.57 | |
| 29105 | <1% | 29 | $166.11 | |
| 87210 | <1% | 34 | $158.68 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 38 | $156.84 |
| 85007 | <1% | 81 | $152.81 | |
| 73660 | <1% | 12 | $149.81 | |
| 85379 | <1% | 14 | $146.36 | |
| 76882 | <1% | 12 | $145.48 | |
| 82553 | <1% | 12 | $141.22 | |
| 0272 | <1% | 29 | $133.31 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 52 | $113.02 |
| 84550 | <1% | 24 | $109.43 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 347 | $105.00 |
| 0636 | <1% | 15 | $75.48 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 12 | $75.47 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 31 | $73.74 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 43 | $44.12 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 129 | $37.97 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 14 | $35.96 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 27 | $30.80 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 32 | $24.27 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 31 | $7.66 |
| 0259 | <1% | 17 | $0.09 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 55 | $0.00 |
| 96376 | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOAN, CHRISTOPHER (MANAGING ASSOCIATE GENERAL COUNSEL)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.